Merck Enters Cancer Vaccine Collaboration With Geron

Merck acquires expertise in telomerase-targeting cancer vaccines in a deal with Menlo Park, Calif.-based Geron. Under the agreement, Geron will receive an upfront payment, milestone payments and royalties. Merck also gains the option to partner on Geron’s investigational prostate cancer vaccine.